A 24-months, prospective, longitudinal study of Natalizumab in patients with Relapsing Remitting Multiple Sclerosis (RRMS) assessing lymphocyte subsets modification and their correlation with anti-JCV antibody index
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 15 Aug 2017 Results published in the Journal of Neuroimmunology
- 27 Feb 2016 New trial record